Companies across the globe are working towards the development of new treatment therapies for Uveal Melanoma. Some of the key players in the therapeutic market of uveal melanoma are Delcath Systems, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma, and others.
DelveInsight’s “Uveal Melanoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uveal Melanoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Uveal Melanoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Uveal Melanoma Overview
Melanoma, a form of skin cancer, develops when melanocytes—cells responsible for producing melanin and giving skin its tan or brown hue—undergo uncontrolled growth. While it often originates in a mole on the skin (known as skin melanoma), melanoma can also affect the eyes, where melanin-producing cells exist, leading to a condition called ocular melanoma.
Uveal melanoma, also referred to as intraocular melanoma, stands as the most prevalent malignancy in adults, constituting approximately 85% of ocular melanomas. This rare cancer stems from melanocytes situated within the uveal tract. The majority of cases, around 85%-90%, involve the choroid, with the remaining instances occurring in the iris or ciliary body. Typically, mutations in GNAQ or GNA11 genes trigger its onset.
Individuals with atypical mole syndrome, dysplastic nevus syndrome, or ocular/oculodermal melanocytosis are more prone to uveal melanoma. Due to its heightened risk of metastasizing beyond the eye, ophthalmologists and oncologists adopt aggressive treatment approaches to curb its spread.
Uveal Melanoma Market Key Facts
-
As per Ahmad et al. (2021), the overall age-standardized incidence rate (ASIR) of uveal melanoma in Germany was 6.41 person per million.
-
According to a study by Vidal et al. (2020), in Spain, the incidence of Uveal melanoma ranges from 5.3 to 10.9 cases per million inhabitants per year.
-
As per Gristani and Tura (2018), GNAQ mutation was noted in 45–49% of uveal melanoma biopsy samples, whereas GNA11 mutations have been noted in 31.9% of uveal melanoma samples.
-
According to Kaneko (2021), in the Japanese population, the incidence of uveal melanoma was found to be 0.25 per million.
-
As per the study by Neumann et al. (2019), the incidence of uveal melanoma in Europe was found to be approximately 6 per million.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Uveal Melanoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Uveal Melanoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Uveal Melanoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Uveal Melanoma Epidemiology Segmented by –
-
Total Incident Cases of Uveal Melanoma in the 7MM (2019–2032)
-
Stage-specific Cases of Uveal Melanoma in the 7MM (2019–2032)
-
Site-specific Cases of Uveal Melanoma in the 7MM (2019–2032)
-
Mutation-specific cases of Uveal Melanoma in the 7MM (2019–2032)
-
Total Treated Cases of Uveal Melanoma in the 7MM (2019–2032)
Uveal Melanoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Uveal Melanoma market or expected to be launched during the study period. The analysis covers the Uveal Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Uveal Melanoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Uveal Melanoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/uveal-melanoma-market
Uveal Melanoma Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Intraocular (Uveal) melanoma. Currently, BioMed Valley Discoveries, Inc. is leading the therapeutics market with its Intraocular (Uveal) melanoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Uveal Melanoma Therapeutics Market Include:
-
Novartis Pharmaceuticals
-
Foghorn Therapeutics
-
TriSalus Life Sciences, Inc.
-
Bristol Myers Squibb
-
Array BioPharma
-
Ono Pharmaceutical
-
AstraZeneca
-
Roche
-
IDEAYA Biosciences
-
Merck & Co
-
GlaxoSmithKline
-
Janssen
-
Delcath Systems
-
Aura Biosciences
-
Seagen
-
Ascentage Pharma
And Many Others
Uveal Melanoma Therapies Covered in the Report Include:
-
BVD-523: BioMed Valley Discoveries, Inc
-
AU-011: Aura Biosciences, Inc
-
PAC-1: Vanquish Oncology
-
Melphalan: Delcath Systems
-
SEA-CD40: Seagen
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/uveal-melanoma-marketTable of Content (TOC)
1. Key Insights
2. Executive Summary
3. Uveal Melanoma Competitive Intelligence Analysis
4. Uveal Melanoma Market Overview at a Glance
5. Uveal Melanoma Disease Background and Overview
6. Uveal Melanoma Patient Journey
7. Uveal Melanoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Uveal Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Uveal Melanoma Unmet Needs
10. Key Endpoints of Uveal Melanoma Treatment
11. Uveal Melanoma Marketed Products
12. Uveal Melanoma Emerging Drugs and Latest Therapeutic Advances
13. Uveal Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Uveal Melanoma Market Outlook (In US, EU5, and Japan)
16. Uveal Melanoma Access and Reimbursement Overview
17. KOL Views on the Uveal Melanoma Market
18. Uveal Melanoma Market Drivers
19. Uveal Melanoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/